Navigation Links
Functional Cloning Using,,,ViraPort Retroviral cDNA Expression Libraries


Retroviral libraries with high-titer efficiency and larger insert potential

Functional Cloning Using
ViraPort Retroviral cDNA Expression Libraries

Katherine Felts Kim Zaharee Latha Sundar Jamie Limjoco
Anna Waesche Peter Vaillancourt
Stratagene

We introduce a set of human cDNA expression libraries inserted into the high-titer retroviral vector pFB. ViraPort retroviral libraries allow complex cDNA libraries to be efficiently introduced into virtually any mitotic cell type for screening based on gene function. The cDNA copy number per cell can be easily controlled by adjusting the multiplicity of infection (MOI). In this way, cell populations may be generated in which greater than 90% of infected cells contain one-to-five cDNAs. We describe the isolation of two known oncogenes and one cell-surface receptor from one of the libraries (Burkitts Lymphoma).

Gene Class

Selection/Screen

Cell-surface proteins

FACS sorting

Extracellular receptors

FACS sorting

Proliferation or survival

Growth factors

Factor-dependent growth

Oncogenes

Loss of contact-inhibition

Cell-cycle proteins

Loss of contact-inhibition

Phenotypic complementation

Signaling proteins

Loss of contact-inhibition

Phenotypic complementation

Reporter activation

Transcription factors

Reporter activation

Apoptosis inhibitors

Survival: resistance to apoptosis inducers

Metastasis-inducing genes

In vivo metastasis

In vitro invasion

Differentiation-inducing genes

Phenotype: differentiation

Ion channels

Phenotype: ion-specific indicator or tracer

Expression cloning allows genes to be identified and isolated based on gene function or phenotype in the absence of any prior knowledge of protein or nucleic acid sequence. A wide range of gene types have been cloned from complex cDNA libraries using functional assays that allow a specific trait to be selected or screened (Table 1).1 Originally, hybrid selection, direct transfection of plasmid expression libraries, and transfection of genomic DNA were successfully used to clone growth factors, cell surface proteins, and transcription factors. However, selected cells or cDNA pools usually contained a large number (often hundreds) of extraneous clones in addition to the target cDNA of interest, necessitating several rounds of laborious DNA isolation and rescreening before the gene of interest is identified.

The use of retroviral vectors for expression cloning has several advantages over traditional methods. Recent advances in viral packaging systems ensure that virtually any cell type can be transduced with efficiencies approaching 100%.2 Additionally, the copy number of individual cDNA expression cassettes can be easily controlled by varying the MOI. Hence, populations of infected cells may be generated in which greater than 90% of the cells are transduced with one-to-five individual cDNAs per cell, greatly reducing the time and labor required to isolate the gene of interest.3 The Moloney Murine Leukemia Virus (MMLV)-based vectors have a large insert capacity (8.0 kb).4 The retroviral vectors integrate into transcriptionally active regions of the host genome, and two days following infection, a collection of stable cells are produced in which there is minimal clonal variegation of expression from cell to cell. Finally, improved transfection methods have allowed transient production of high-titer viral supernatants containing representative mixtures of cDNAs without the concern of clonal skewing, which likely occurs with the production of stable producer cell lines.5

Fig.1

We have produced ViraPort retroviral cDNA expression libraries in the high-titer vector pFB6 (Figure 1A). This vector is an MMLV-based vector in which titers of 107 to 108 colony forming units (cfu)/ml are routinely achieved using 293 cell-based transient packaging systems. We validated the use of ViraPort libraries for functional cloning by screening the human Burkitts Lymphoma cDNA library for oncogenic cDNAs.

cDNA Library Construction

Polyadenylated mRNA was isolated from various human tissues or cell lines by two cycles of purification with oligo dT-cellulose. Double-stranded cDNA was synthesized using Stratagenes cDNA synthesis kit, and size-selected cDNA was inserted between the EcoR I and Xho I sites of the plasmid pFB (Figure 1A). The pFB vector has an extended packaging site and uses the viral splice donor and splice acceptor configuration from the high-titer, high-expressing vector pMFG.7 To minimize packaging size constraints, and because the high infection efficiency of the system obviates the need for selection of transduced cells, there are no selectable markers in this vector. To assess the quality of both the phosphatase-treated EcoR I/Xho I-digested vector as well as the quality of the Daudi cDNA, XL10-Gold ultracompetent cells were transformed with ligated plasmid. Miniprep DNA from 100 of the resultant colonies was digested and analyzed. All of the 100 clones examined had EcoR I/Xho I-excisable inserts, with an average size of 1.7 kb and a size range of 0.5 to 5.0 kb (data not shown). Primary clones (1.1 x 106) were amplified to construct the pFB Daudi library. Figure 2 shows the size distribution for 20 representative cDNAs from this library.

Fig.2

Functional Cloning Strategy

In the schematic showing a general strategy for functional cloning using ViraPort libraries (Figure 1B), high-titer viral stocks were transiently produced by transfecting a 293 cell-based retroviral producer line 8,9 with the plasmid cDNA library, then harvesting cell supernatants after 2 days. Alternatively, 293 or 293T cells (ATCC) may be cotransfected with the plasmid library in addition to one or more expression vectors that provide the viral structural proteins gag, pol, and env in trans.10,11 We used the former method for this study and achieved a titer of approximately 107 cfu/ml, as determined by RT-PCR using the prostar HF RT-PCR system12 and vector-specific primers. After an additional one or more days, cells were selected or screened for the desired phenotype, and colonies or selected populations were expanded and either enriched by one or more cycles of selection or analyzed directly. Genomic DNA was then isolated, and the cDNA inserts were retrieved by PCR using vector-specific primers that flank the insert. The PCR products were then subcloned into high-efficiency PCR cloning vectors (e.g., PCR-Script or pCMV-Script vectors) that allow sequencing of the insert and further functional analysis.

Expression Screening for Oncogenes

The ability of oncogene expression to confer deregulated growth on certain contact-inhibited cell lines, such as NIH3T3 fibroblasts, is a proven, powerful tool for identifying and isolating natural oncogenes, as well as genes involved in signal transduction pathways and cell cycle regulation.13 Constitutive expression or truncation of many of these latter classes of genes leads to a loss of contact inhibition and, thus, focus formation in NIH3T3 cells.

Focus #

Insert size (kb)

cDNA recovered

Onco-A

2.3

vav-1 oncogene

Onco-1

1.5

Mitochondrial phosphate carrier

1.2

Gamma interferon-inducible protein

2.2

Transcriptional repressor of known cell-cycle regulatory protein
(to be discussed in a future article)

Onco-2

2.0

raf-1 oncogene

Onco-3

2.0

raf-1 oncogene

Onco-4

2.0

raf-1 oncogene

Onco-11

0.5

Human ribosomal protein L8

1.6

Unknown (pac clone; chromosome 11)

0.9

HL5 proteosome-associated protein

1.2

Porin

1.1

MHC

1.5

proteosome

1.4

translation initiation factor

0.9

Unknown

1.1

Unknown

Onco-12

2.5

raf-1 oncogene

Onco-13

2.5

vav-1 oncogene

Onco-20

2.7

vav-1 oncogene

The pFB Burkitts Lymphoma (Daudi) library was screened for the presence of oncogenes by first infecting low-passage NIH3T3 cells, then isolating and expanding foci after 28 days. Uninfected NIH3T3 cells were maintained as a negative control. Focus formation was observed in both uninfected and infected cell populations. Approximately three times as many foci were observed on the infected plates, and, of those, a number of foci had unusual morphologies not observed on the control plates. Twenty-four of the largest and most aggressively growing foci on the test plates were picked and expanded. Genomic DNA was extracted from nine of the clones, and cDNA inserts were PCR-amplified, subcloned, and sequenced. Due to the relatively high MOI used in this screen, none of the foci had less than four individual cDNA inserts, and one of the foci (Onco-11, Table 2) had as many as nine individual cDNAs. Seven of the nine foci examined harbored cDNAs encoding N-terminally truncated versions of the signaling proteins raf-1 and vav-1, which have been shown to be potent transforming proteins when truncated at their N-termini.13. Onco-1 contained a gene encoding a transcriptional repressor of a known cell cycle regulatory protein. It is not surprising, therefore, that constitutive expression of this cDNA might lead to unregulated cell growth. Onco-11 contained nine distinct cDNAs, none of which were obvious candidates for oncogenic transformation, and three of which were unknown. Like Onco-1 and Onco-11, all seven of the raf-1 and vav-1 foci harbor at least three additional cDNAs (not shown in Table 2). These additional cDNAs were distinct from each other and from focus to focus, an observation expected for a complex, representative cDNA library for which no selection applies other than that for the single focus-forming oncogene.

Receptor Cloning from ViraPort Retroviral Libraries

Fig.4

It is possible to clone cell-surface receptors by expression screening, provided that a receptor ligand or receptor-specific antibody is available. We screened for the IL-4 receptor (IL-4 R), which is known to be expressed on the surface of Daudi cells. NIH3T3 cells were infected at an MOI of approximately one, and, after 2 days, the cells were labeled with receptor-specific monoclonal antibody followed by a fluorescent anti-mouse IgG secondary antibody. The cells were then FACS sorted, and the sorted population was expanded for 10 days and sorted a second time. Approximately 3% of the expanded population from the first sort was collected in the second sort (Figure 4A) and expanded an additional 10 days. FACS analysis of the twice-sorted population indicated that over 90% of the cells reacted with the receptor-specific antibody. PCR reactions were performed using vector-specific primers, which flank the cloning site, and genomic DNA was isolated from either uninfected NIH3T3 cells or from the sorted population as template. Figure 4B shows a prominent 1.7-kb band that was observed for the sorted population (Lane 3), whereas no PCR product exists for the uninfected control (Lane 2).

The 1.7-kb PCR product was subcloned, sequenced, and found to encode not the IL-4 R but the human IgG FcaRII receptor, a receptor found on most hematopoietic cell types that recognizes the Fc domain of IgG antibodies.14 Although the a-IL-4 R monoclonal antibody used in the FACS sort was derived from mouse cells, it is not surprising that the human IgG Fc receptor can recognize the Fc region of murine IgG because there is a high degree of homology between both the murine and human IgG constant regions, as well as between their respective IgG FcaRII receptor chains.14 Thus, the a-IL-4 R antibody functioned in this screen not as an IL-4 R-specific antibody but as an IgG FcaRII-specific ligand. This serves to better illustrate the power of FACS for receptor cloning because, when screening for an unknown receptor, it is more likely to have at hand receptor-specific ligand rather than receptor-specific antibody.

Conclusions

ViraPort retroviral libraries can be used in a wide range of applications and are limited only by the ability to devise a functional screen for the desired target gene. In addition, libraries comprising a complex spectrum of mutants derived from a single gene can be screened for dominant positive or negative mutations or for other altered or enhanced phenotypes.1 The availability of packaging systems that use polytropic envelope proteins, such as 10A1 and VSV-G, will allow functional screening in essentially any mitotic cell type.2 Finally, the relatively high titers and high expression levels that can be attained using the pFB vector backbone6 increase the probability of being able to identify the desired cDNA from a complex, fully representative library.

Acknowledgments

The authors thank Dr. Gary P. Nolan (Stanford), Dr. John Wu (Berlex), Mei Vaillancourt (Canji), Dr. Mary Simcox (Hoffman-La Roche), Dr. Ronda Allen, Keith Chen, Tanya Hosfield, Milan Miletic, John C. Bauer, Dr. Alan Greener, Dr. Joe Sorge, Dr. Cathy Chang, Tim Sanchez, Connie Hansen, Elliott Gorfain, and Mike Kobrin for helpful discussions and technical assistance.

REFERENCES

  1. Kitamura, T. (1998) Intern. J. Hematol. 67: 351-359.

  2. Miller, A.D. (1997). In Retroviruses (Eds. Coffin, J.M., Hughes, S.H., and Varmus, H.E.) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. pp. 437-473.

  3. Onishi, M., et. al. (1996) Exp. Hematol. 24: 324-329.

  4. Riviere, I and Sadelain, M. (1997) In Methods in Molecular Medicine: Gene Therapy Protocols (Ed. Robbins, P.D.) Humana Press, Totawa, New Jersey. pp. 59-78.

  5. Kitamura, T., et. al. (1995) Proc. Natl. Acad. Sci. USA 92: 9146-9150.

  6. Felts, K., et. al. (1999) Strategies 12: 74-77

  7. Riviere, I., et. al. (1995) Proc. Natl. Acad. Sci. USA 92: 6733-6737.

  8. Pear, W.S., et. al. (1997) In Methods in Molecular Medicine: Gene Therapy Protocols (Ed. Robbins, P.D.) Humana Press, Totawa, New Jersey. pp. 41-57.

  9. Kinsella, T.M. and Nolan, G.P. (1996) Hum. Gen. Ther. 7: 1405-1413.

  10. Soneoka, Y., et. al. (1995) Nuc. Acids Res. 23(4): 628-633.

  11. Yang, S., et. al. (1999) Hum. Gen. Ther. 10: 123-132.

  12. Borns, M., et. al. (1999) Strategies 12: 33-36.

  13. Hesketh, R. (1997) The Oncogene and Tumour Suppressor Gene Facts Book. Academic Press, San Diego.

  14. Brooks, D.G., et. al. (1989). J. Exp. Med. 170: 1369-1385.


'"/>

Source:


Page: All 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Epitope-Tagging Vectors for Functional Analysis in Yeast
2. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
3. Isolation to Functional Analyses
4. Precursor miRNAs for Successful miRNA Functional Studies
5. Using Validated siRNAs in Functional Genomic Assays
6. Whole Gel Eluter Purification of a Functional Multiprotein DNA Replication Complex, Rev A
7. Sciclone ALH 3000 Liquid Handler: Functional Characterization of the High Volume Head - Part 1: Plate-to-Plate Precision Testing
8. New Yeast Cloning System for Producing Proteins with Native Amino Acid Sequences
9. Enhanced PCR Cloning System
10. pfuturbo DNA Polymerase: A High-Performance, High-Fidelity Enzyme Ideal for PCR Cloning
11. Mammalian Expression Vector for Efficient Cloning of PCR Fragments
Post Your Comments:
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
(Date:12/1/2009)INCLINE VILLAGE, Nev., Dec. 1 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced revenue guidance for the fourth quarter ended December 31, 2009 of approximately $57 million, as compared with
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3
...- Biomedical engineers at The University of Texas ...ave announced pre-clinical test results in the Sep...edicine demonstrating the feasibility of a smart p... in glucose or blood sugar levels and releases ins...tions of the pancreas which produces the blood-sug...
...nc. (Nasdaq:,SQNM) today announced that a live aud...l be provided for its analyst and investor briefin...the event are as follows: (Logo: http://www.new... Sequenom Today and Tomorrow, When: Monday...here: http://www.sequenom.com , How: Liv...
...l Alliance, the leading,management consulting firm...dustries, today announced that Ben Bonifant, Vice ...ent practice, will moderate a panel discussion,at ...rence hosted by,Windhover Information. The confere...iott Financial Center in New York City. The panel...
Other Biology Technology:Smart insulin nanostructures pass feasibility test, UT study reports 2Sequenom to Webcast Analyst and Investor Briefing Presentation on September 24 2Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference 2Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference 3
(Date:12/4/2009)The electroencephalogram (EEG) is widely used by physicians and scientists to study brain function and to diagnose neurological disorders. However, it has remained largely unknown whether the electrod
(Date:12/4/2009)Using a new mathematical model of heart cells, University of Iowa investigators have shown how activation of a critical enzyme, calmodulin kinase II (CaM kinase), disrupts the electrical activity of h
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
Breaking Biology News(10 mins):How to read brain activity? 2U-Iowa study helps advance heart-related research 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Biopolymers Symposium 2009 Teams with Carbonfund org to Create a Zero Carbon Event 13295 1Biopolymers Symposium 2009 Teams with Carbonfund org to Create a Zero Carbon Event 13295 210 Steps to Affordable Health Care Overhaul 3A NCPA Proposes Reforms to Protect Choices Control Costs and Preserve Access 53252 110 Steps to Affordable Health Care Overhaul 3A NCPA Proposes Reforms to Protect Choices Control Costs and Preserve Access 53252 2Human Pheromones 3A Whats Purported Whats Supported A White Paper Published by The Sense of Smell Institute 53249 1
... for Medical Research (Burnham) have discovered a ... Sporadic Inclusion Body Myositis (sIBM). sIBM is ...men, causing muscles to gradually weaken and waste...known, but it is the most common muscle disease am...iliarity, it is probably underdiagnosed. This disc...
...cal Research Institute report that bats significan...In a lowland tropical rainforest in Panama, bats c...cts as do birds. This landmark study in the journa...ats and birds to protect plants via insect predati...dy by the authors suggested that bats were underes...
... University have pinpointed a small group of genes...w to produce a hormone that is key to their develo...ich hormone production in plants affects both a pl...nvironments. , Dr. Jose Alonso, assistant profes...nt biologists from NC State, Germany and the Czech...
Other Biology News:RING finger protein 5 may guide treatment for muscle disease in older adults 2RING finger protein 5 may guide treatment for muscle disease in older adults 3Smithsonian researchers show major role of bats in plant protection 2NC State researchers identify genes key to hormone production in plants 2
Rabbit Anti-QKI Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Acridinium Ester Trigger Solutions from Assay Designs/Stressgen Bioreagents
Mouse Anti-St. Louis encephalitis Monoclonal Antibody, Unconjugated, Clone 6B5A-2 from ABR-Affinity BioReagents
...bbit polyclonal to Kv4.2 Immunogen Synthetic pep...rresponding to amino acids 23-43 of Rat Kv4.2. Re...cted to cross-react with Human (100% identity with... Rabbit (100% identity with immunogen) and Ferret ...
Biology Products: